Seguridad y eficacia en el tratamiento de la dermatitis atópica severa con ciclosporina A y factor de transferencia

Revista Alergia Mexico

Volumn 46, Issue 2, 1999, Pages 49-57

  Miranda, Miguel Angel Cordero ^a   Sandoval, Graciela Flores ^b   Solang, Modesto Orea ^c,e   Parra, Sergio Estrada ^d   Miranda, Ernestina Serrano ^d  

^a Residente Q

^b Medica Adscrita Serv A

^c ISSSTE

^d INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^e HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

Author keywords

Ciclosporine A; Severe atopic dermatitis; Transfer factor; Treatment

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN E; TRANSFER FACTOR;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; FEMALE; GENE ACTIVATION; HEADACHE; HUMAN; HYPERTRICHOSIS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MALE; REVIEW; RHINITIS;

EID: 0032835039     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Hanifin JM, Atopic dermatitis. In: Middleton E, Reed CE, Ellis EF. Allergy: Principles and practice. St Louis: Mosby, 1991: 77-98.
2. Hanifin JM, Lobitz WC. Newer concepts of atopic dermatitis. Arch Dermatol 1997; 113: 663-70.
3. Hanifin JM, Rajka G. Diagnosis features of atopic dermatitis. Acta Derm Venereol 1980; 92(Suppl 1): 44-7.
4. Sehgal VN, Jain S. Atopic dermatitis: clinical criteria. Int J Dermatol 1993; 32(9): 628-37.
5. Bos JD, Smith JH and Kapsenberg NIL. Pathogenesis of atopic eczema. Lancet 1994; 343: 1338-41.
6. Leung DYM. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997; 107(Suppl 1): 25-30.
7. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clones. Definition according to profiles of lymphokine activics and secretory proteins. J Immunol 1986; 136: 2348-57.
8. Mosmann T, Coffman R. Heterogenicity of cytokine secretion patterns and function of helper T cell. Adv Immunol 1989; 46:111-47.
9. Vercelli D, Geha RS. Regulation of IgE synthesis: from membrane to the genes. Springer Semin Immunopathol 1993; 115: 5-16.
10. Pene J, Rousset F, Briére F. IgE production by normal human lymphocytes is induces by interleukin 4 and suppressed by interferons y, a-and prostaglandin E2. Proc Natl Acad Sci USA 1988; 85: 6880-4.
11. Yu B, Sawal T, Uchara M, et at. Immediate hypersensitivity skin reactions to human dander in atopic dermatitis. Arch Dermatol 1988; 124:1530-3.
12. Firmerty JP, Summerell S, Rolgate ST. Relationship between skin-Prick test, the multiple allergosorbent test and symptoms of allergy disease. Clin Exp Allergy. 1989; 19: 51-6.
13. Wedi B, Raap U, Kaap A, Delayed cosinophil programmed cell death in vitro. A common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997; 100: 536-43.
14. Juhun L, Johansson SG, Bennich H, et al. Immunoglobulin E dermatoses: Levels in atopic deramatitis and urticaria. Arch Dermatol 1969; 100: 12-6.
15. Ogawa M, Berger PA, Mclntyre O.R, et al. IgE in atopic dermatitis. Arch Dermatol 1971; 103: 575-80.
16. Uehara M. Heterogeneity of serum IgE levels in atopic dermatitis. Act Derm Venerol (Stock) 1986; 66: 404-8.
17. Bruijnezeel-Koomen C, Van Reysen F, Mudde GC. IgE and atopic dermatitis. Clin Exp Allergy 1991; 21(1): 294-301.
18. Wuthrich B. Serum IgE in atopic dermatitis. Relationship to severity of cutaneous involvement and course of disease as well as coexistence of atopic respiratory disease. Clin Exp Allergy 1978; 8:241-8.
19. Abeshira-Amar O, Gilbert M, Joly M, et al. IL-4 plays a dominant role in the differential development of TH0 into Th1 and Th2 cells. J Immunol 1992; 148: 3820-9.
20. Bradding P, Feather I, Howarth P, et al. Interleukin-4 is localized to and release by human mast cell. Exp Med 1992; 176:13 81-6.
21. Ricci M. EL-4: a key cytokine in atopy. Clin Exp Allergy 1994:24:8-12.
22. Aly R. Bacteriology of atopic dermatitis. Acta Derm Venercol (Stockh) 1980; 92 (Suppl), 16-8.
23. White MI, Noble WC. Consequences of colonization and infection by Staphylococcus aureus in atopic dermatitis. Clin Exp Dermatol 1988; 119: 189-98.
24. Lobitz WC, Honeyman JF, Winkler NW. Suppressed cell mediated immunity in two adults with atopic dermatitis. Br J Dermatol 1972; 86: 317.
25. McGready SJ, Buckiey RH. Depression of cell-mediated immunity in atopic eczema. J Allergy Clin Immunol 1975; 56: 393-4.
26. Rogge JL, Hanifin JM. Delayed cutaneous hypersensitivity and lymphocyte transformation; disassociation in atopic dermatitis. Arch Dermatol 1979; 115:36-8.
27. Leung D, Rhodes A, Geha R. Enumeration of T cell subset in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1981; 67:450-5.
28. Chan S, Kim J, Henderson W et al. Altered prostaglandin E2 regulation of cytokine production in atopic dermatitis. J Immunol 1995; 151: 3345-52.
29. Kieffer M, Bergbríant L, Faergmann J, et al. Immune reactions to Pityrosporum, ovale in adult patients with atopic and seborrcic dermatitis. J Ann Acad Dermatol 1990; 22: 739-42.
30. Leung DYM, Harbeck L, Hanifin JM. Presence of IgE antibodies to staphilococcal exotoxins on the skin of patients with atopie dermatitis: evidence for a new group of allergens. J Clin Invest 1993; 92:1374-80.
31. Shustcr S, Fisher GH, Harris E, et al. The effect of skin disease on self image. Br J Dermatol 1990; 99 (suppl. 16): 18-19.
32. Logan PA. Self help groups for patient with chronic skin disease. Br J Dermatol 1988; 118: 505-7.
33. Schmeider L, Baz Z, Zarcone C, et al. Long term therapy with recombinant interferon gamma for atopic dermatitis. An Allergy Asthma Immunol 1998; 263-8.
34. Boguniewiez M, Jaffe HS, Izu A, et al. Recombinant interferon-gamma in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88: 365-70.
35. Hanifin J, Schneider LC, Leung DYM, ct al. Recombinant interferon gamma therapy for atopic dermatitis. I Am Acad Dermatol 1993; 28: 189-97.
36. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996; 107(1): 51-6.
37. Hederos CA, Berg A. Epogam evening primrose oil treatment in atopic dermatitis and asthma. Arch Dis Child 1996; 75 (6): 494-7.
38. Businco L, Mcglio P, Amato G, et al. Evaluation of the efficacy of oral cromolyn sodium or an oligo antigenic diet in children with atopic dermatitis: a multicentcr study of 1085 patients. J Invest Allergol Clin Immunol 1996; 6(2): 103-9.
39. Kawashirna M, Nakagawa H, Ohtsuki M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis (letter). Lancet 1996; 348 (9036): 1240-1.
40. Graham BR- Managing adults with atopic dermatitis. Dermatol Clin 1996; 14(3): 531-7.
41. Fudenberg HR. Tranfer Factor, past, present and future. Ann Rev Pharmacol Toxicol 1989; 29: 475-516.
42. Kirkpatrick CH, Tranfer Factor. J Allergy Clin Immunol 1993; 81(5):803-13.
43. Rozzo SJ, Kirpatrick CH. Purification Transfer Factor . Molecular Immunology 1992; 29: 175-82.
44. Estrada PS, Cabezas-Quiroga R. El Factor de Transferencia como agente tcrapćutico. Temas de Inmunofarmacología: los estimulantes 1993: 19-37.
45. Navarro CD, Estrada PS, Flores SG, et al. Factor de transferencia en dermatitis atópica moderada y severa. Revista Alergia México 1996;43(5):116-23.
46. Jones JB, Brown RA, Marks I, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136: 76-81.
47. Van Joost TH, Heulc F, Koi-stanje M et al. Cyclosporin in atopic dermatitis. A multicentre placebo controlled study. Br J Dermatol 1994; 130: 634-40.
48. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double blind, placebo, controlled trial. Br J Dermatol 1993; 129: 422-30.
49. Sowden JM, Berth Jones J, Ross JS et al. A multicentre double-blind, placebo-controlled crossover- study to asses the efficacy and safety of cyclosporin in adult patients with severe refractory atopic dermatitis. Lancet 1991; 338:137-40.
50. Zaki I, Emerson R and Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporine. Br J Dermatol 1996; 135(Suppl 48): 21-4.
51. Berth-Jones J, Finlay AY, Zaki L, et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. J Am Acad Dermatol 1996; 34:1016-21.
52. Gupta AK, Brown NM, Ellis CN, et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989; 21: 1245-56.
53. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38.
54. Renuzzi G, Bertani T. Renal vascular and thrombotic effects of ciclosporine. Am J Kidney Dis 1989; 1: 261-72.
55. Kopp JB, Klotman P. Cellular and molecular mechanism of ciclosporine nephrotoxicity. J Am Soc Nephrol 1990; 1: 162-79.
56. Edwards BD, Testa HJ, Lawson RS et al. Nifedipine modulates the haemodynamics of vasoactive regulation of cyclosporine neprhotoxicity in the normal human kidney Br J Dermatol 1990; 123:811.
57. Van Joost T, Stolz E Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987; 123: 166-7.
58. Logan RA, Camp RD. Severe atopic eczema: response to oral cyclosporine A. J R Soc Med 1988; 81: 417-418.
59. Molley RJ, Whittaker JA, Holt PJ. Resolution of atopic dermatitis in a patient treated with cyclosporine. Clin Exp Dermatol 1989; 14: 243-4.
60. Gold ME, Picascia DD, Roenigk HH Jr. Treatment-resistant atopic dermatitis controlled with cyclosporine A. Int J Dermatol 1989, 28 481-2.
61. Anderson J, Nagi S, Groth CG, et al. Effects of FK506 and Cyclosporine on cytokine production studied in vitro at single cell level . Immunology 1992; 75: 136-42.
62. Kubin M, Kormorinn M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human cells. J Exp Med 1994; 180: 211-22.